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A De Novo FOXP1 Truncating 
Mutation in a Patient Originally 
Diagnosed as C Syndrome
Roser Urreizti1, Sarah Damanti2,3, Carla Esteve1, Héctor Franco-Valls1, Laura Castilla-Vallmanya1, 
Raul Tonda4,5, Bru Cormand1, Lluïsa Vilageliu1, John M. Opitz6, Giovanni Neri7, Daniel Grinberg1 & 
Susana Balcells1
De novo FOXP1 mutations have been associated with intellectual disability (ID), motor delay, autistic 
features and a wide spectrum of speech difficulties. C syndrome (Opitz C trigonocephaly syndrome) is a 
rare and genetically heterogeneous condition, characterized by trigonocephaly, craniofacial anomalies 
and ID. Several different chromosome deletions and and point mutations in distinct genes have been 
associated with the disease in patients originally diagnosed as Opitz C. By whole exome sequencing 
we identified a de novo splicing mutation in FOXP1 in a patient, initially diagnosed as C syndrome, who 
suffers from syndromic intellectual disability with trigonocephaly. The mutation (c.1428 + 1 G > A) 
promotes the skipping of exon 16, a frameshift and a premature STOP codon (p.Ala450GLyfs*13), 
as assessed by a minigene strategy. The patient reported here shares speech difficulties, intellectual 
disability and autistic features with other FOXP1 syndrome patients, and thus the diagnosis for this 
patient should be changed. Finally, since trigonocephaly has not been previously reported in FOXP1 
syndrome, it remains to be proved whether it may be associated with the FOXP1 mutation.
Severe neurodevelopmental disorders (NDD) affect more than 3% of children and are due to a genetic defect 
in more than 80% of the cases1. Until recently, the main diagnostic tools include a great variety of molecular 
tests (karyotype, array CGH and Sanger sequencing of putative candidate genes) together with multiple clinical 
evaluations by highly specialized physicians and a variety of complementary tests, some of them invasive, such 
as neuroimaging, metabolic evaluation or cerebrospinal fluid examination1. After this “diagnostic odyssey” more 
than a half of the patients are still miss- or undiagnosed2 and this situation is worsened in patients suffering from 
rare diseases clinically and genetically heterogeneous or with unclear or atypical presentations2,3. Next-generation 
sequencing (NGS) has revolutionized the field of clinical genetics by highly improving the diagnostic yield of rare 
diseases, and facilitating the identification novel causative genes3, achieving a molecular diagnosis in 25–68% of 
the cases4.
FOXP1 is one of the genes recently found mutated in a Mendelian developmental disorder. Heterozygous 
sequence variants have been linked to intellectual disability (ID) with language delay, with or without autis-
tic features (MIM #613670). The FOXP1 (forkhead-box protein P1; MIM 605515) protein is a member of the 
forkhead-box family of transcription factors characterized by a highly conserved forkhead DNA-binding domain 
(FOX) and with crucial roles in embryonic development5,6. The FOXP1 protein, as other members of the FOXP 
family, includes 4 main functional domains: a N-terminal glutamine (Gln) rich region, zinc finger and leucine 
zipper domains and a C-terminal FOX domain (Fig. 1).
FOXP1 is important in neural development7, monocyte differentiation and macrophage function5. It has 
also been described as an oncogene in hepatocellular carcinoma, pancreatic cancer, and various types of B-cell 
non-Hodkgin lymphomas8, being yet another example of the tight connection between cancer-related genes and 
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developmental defects9. Most FOX proteins bind to their target DNA sequences as monomers, except members 
of the FOXP subfamily, which include FOXP1–4. FOXP1 is able to form both homo and heterodimers (with 
its paralogous FOXP2) via the leucine zipper domain10,11. In mouse, Foxp1 and Foxp2 have been shown to be 
co-expressed in several brain regions12 as well as in perichondrial skeletal progenitors and proliferating chondro-
cytes during endochondral ossification and they act as coordinators of osteogenesis and chondrocyte hypertrophy 
in the developing long bones13. In humans, FOXP2 is involved in a rare form of speech and language disorder 
with developmental verbal dyspraxia (childhood apraxia of speech or CAS, MIM #602081).
Here we present an adult patient with developmental delay, trigonocephaly, speech impairment and ID who 
was diagnosed as Opitz C syndrome early in life, in whom we have identified by WES a novel splicing mutation in 
the FOXP1 gene and provide a detailed clinical description, in comparison to so far reported patients identified 
carrying deleterious FOXP1 mutations.
Results and Discussion
The patient described here (Patient 2 in Urreizti et al.14) is a 23-year-old man, second child of non-consanguineous 
Italian parents. Pregnancy was complicated by threatened abortion. The delivery was vaginal at 40 weeks. Birth 
weight was 3100 g (25th centile) and length 50 cm (25th centile). Apgar scores were 9 and 10, at 1 and 5 minutes, 
respectively. Patient’s karyotype was normal (46,XY), and so were array CGH (at an average resolution of 75Kb) 
and FMR1 sequencing.
He presented with mild macrocephaly (44.5 cm at 4 months and 55 cm at 8 years, which correspond to +1.74 
and +2.0 SD, respectively), peculiar facial appearance (Fig. 2) and premature closure of the metopic suture with 
trigonocephaly (Fig. 2A,B), marked hypertelorism, convergent strabismus, downslanted palpebral fissures, epican-
thus, blepharophimosis (since the first months of life), prominent nasal root and anteverted nostrils (Fig. 2C,D), 
hyperconvolute helix, low-set and posteriorly angulated ears (Fig. 2E), hypoplasia of the malar region, microg-
nathia, highly arched palate and hypertrophy of the alveolar ridges (Fig. 2F). The patient also had large hands and 
long fingers, horseshoe kidney, bilateral cryptorchidism, slight deformity of the forefoot with flat-footedness in 
metatarsal level and clinodactyly of the fifth toes (Fig. 2G,H). He also presented with astigmatism and hypermetro-
pia and had a tendency to form cutaneous keloids. The patient had marked oral and lingual dyspraxia and a 
reduced facial mimicry. As a child, he manifested enuresis and hyperphagia. He underwent: skull remodeling with 
bilateral frontal advancement and re-alignment of the orbital bar, correction of strabismus and cryptorchidism and 
adeno-tonsillectomy for snoring. He is relatively short (158 cm whereas his father’s height is 185 cm).
He was able to sit at 11 months, did not crawl and maintained orthostatism at 14 months, with instability and 
frequent falls. Thereafter, there was an improvement in static and dynamic balance, albeit with an underlying state 
of hypertonicity, postural oddities and serious coordination deficits of fine and large movements. He was able to 
walk autonomously at 3 years, but up to 5 years he was unable to protect himself from falls. From 9 to 12 years 
he was treated with botulinum intra-muscular injections, with only partial and transient benefit. While growing, 
the hypertonic state gradually resolved, but mobility remained clumsy, with toe-walking and an altered dynamic 
equilibrium (use of the trunk movement to maintain balance).
The patient displayed a marked developmental delay in all intellectual milestones. First words were at 2 years 
and complete language was reached at 5 years. During childhood, he had a tendency to repetition and echolalia; 
over time this improved, but the patient had repetitive speech around the same questions. Expressive language 
was affected to a greater degree than receptive language. Furthermore, a substantial disorder of attention and cog-
nitive rigidity prevented adequate learning at school. He manifested features of autism spectrum disorders (ASD), 
such as aggression, hyperactivity, repetitive manipulation of the objects and tendency to explore the environment 
in a purposeless way. He rejected proposals that did not immediately satisfy his own needs, had reduced social 
interaction with a childlike and self-interested attitude and a tendency to search for attention and reassurance. ID 
was of severe degree (IQ 33), with concrete thinking and partial temporal orientation.
The patient was initially diagnosed as C Syndrome (CS, Opitz C trigonocephaly, MIM #211750), a rare condi-
tion whose etiology is still poorly understood and whose diagnosis is still only clinical. CS was initially proposed 
because of trigonocephaly, epicanthus, strabismus, micrognathia, ear anomalies, renal anomalies and severe ID. 
On the other hand, some of the patient’s characteristics did not fit into the C syndrome15: hypertelorism (whereas 
in CS hypotelorism is typical), macrocephaly (instead of microcephaly), downslanted palpebral fissures (instead 
of upslanted) and hypertone (instead of hypotone). After a clinical evaluation at 20 years of age, the patient’s 
diagnosis was changed to “unknown”.
We performed whole-exome sequencing on the patient’s genomic DNA after obtaining written informed consent 
and the approval of the protocol by the Ethics Committee of the Universitat de Barcelona. We found a novel de novo 
truncating mutation in the FOXP1 gene (c.1428 + 1 G > A) in heterozygosis. In addition, we found several variants of 
unknown significance (VUS) in other genes (reported and commented in Table S1). All these variants were inherited 
Figure 1. FOXP1 domain organization (for UniProt Q9H334). Point mutations associated with intellectual 
disability (ID) with language delay, with or without autistic features are shown. In bold, the mutation found in 
the patient described here.
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from either one of his healthy parents and none seems related to the major clinical outcomes of the patient. Of note, the 
patient is homozygous for the missense mutation p.Ala632Thr (rs72468667) at the ASXL1 gene. Truncating mutations 
in this gene are the main cause of Bohring-Opitz syndrome (BOS, MIM #605039), characterized by intellectual disa-
bility and trigonocephaly (present in the patient reported here), together with intrauterine growth retardation, feeding 
difficulties and failure to thrive, and a typical posture (BOS posture), none of which are present in our patient. So far, 
no missense mutations have been found associated with BOS. In addition, mutation p.Ala632Thr has been found in the 
general population in 415 out of 277,188 individuals, including one homozygous individual (data from GenomeAD). 
Whether this missense mutation might contribute to the trigonocephaly of the patient remains an open question.
The FOXP1 mutation found in the patient consists on a c.1428 + 1 G > A transition at the donor splice site of 
intron 16. By means of a minigene strategy, we demonstrated that this change leads to the skipping of exon 16 and 
to a new reading frame starting at alanine 450 and a premature STOP codon after 13 residues (p.Ala450Glyfs*13). 
This truncated protein would lack 214 residues at the C-terminus, including the FOX domain (Fig. 1). Functional 
studies performed on similar truncating mutations (also lacking the terminal FOX domain of the protein) showed 
that they were retained in the cytoplasm16,17 and were unable to repress transcription, as demonstrated by lucif-
erase reported assays. Also, as the majority of the truncating mutations retain the leucine zipper domain, neces-
sary for homo- and heterodimerization (see Fig. 1), they bind the wt FOXP1 and FOXP2 proteins, sequestering 
them in the cytoplasm. This interaction could lead to a dominant negative effect. On the other hand, Sollis et al.17 
found that two truncating mutations (p.Ala339Serfs*4 and p.Arg525*) and the missense mutation p.Trp534Arg 
were unable to interact with wt FOXP1 or FOXP2 and the nuclear localization of the wt FOXP1 and FOXP2 
proteins was unperturbed, ruling out dominant negative effects for these mutations. Additionally, it has been 
described that some of the alleles bearing truncating mutations are degraded by the nonsense-mediated mRNA 
Figure 2. Main features of the patient. (A–B) Neonatal CT scan. Trigonocephaly is clearly appreciated. For 
a control CT scan, see Khanna et al.32 (C–E) Facial dysmorphisms at 2 and 23 years of age. Hypertelorism, 
convergent strabismus, down slanted palpebral fissures, epicanthus, prominent nasal root and ante-verted 
nostrils and (F) arched palate and hypertrophy of the alveolar processes are appreciated. (G–H) Foot phenotype 
with metatarsal flat-footedness and clinodactyly. All images are shared by the family with explicit permission to 
publish.
www.nature.com/scientificreports/
4SCIENTIFIC REPORTS |  (2018) 8:694  | DOI:10.1038/s41598-017-19109-9
decay (NMD)16,18. Finally, several cases have been described with deletions or balanced translocations affecting 
just the FOXP1 gene19–23. A mechanism of loss of function and haploinsufficiency seems to be the common fea-
ture of all mutations associated with FOXP1 disorders, including the one described in our patient.
Table 1 summarizes the main clinical features of FOXP1 patients with published clinical data. It includes 
point mutations (Fig. 1) or small deletions affecting only the FOXP1 gene. In agreement with these patients, the 
patient reported here presented with speech and language impairment (with expressive language more severely 
affected than receptive language) as well as ID and delay in all motor milestones. He also presented with mild 
macrocephaly and hypertelorism, a trait commonly observed in these patients. Autism was diagnosed in 3 of 
8 patients. However, autistic features and/or behavioral problems were observed in all but one of the reported 
patients, including the present one who presented with impulsivity, stereotypic behaviors and reduced social 
interest, among other autistic traits. This is in agreement with the reduced exploratory attitudes and increased 
evasion of social contact, not due to anxiety, observed in mice with a conditional deletion of Foxp1 in brain24. 
Other features shared by the present patient and some of the other FOXP1 cases include relatively short stature, 
strabismus, high-arched palate and enuresis16,17,25,26.
The patient presented here developed blepharophimosis at an early age, same as in the patient described by 
Pariani et al.27, who bears a deletion of the 3p14.1p13 region including the FOXP1, EIF4E3, PROK2 and GPR27 
genes. Our patient also shares epicanthal folds and hypermetropia with the one in Pariani et al., but did not 
display ptosis of the eyelids. In both patients, hypertone was more severe distally and was not associated with 
muscular spasm or distal contractions of the fingers. However, in our case hypertone was not equally distributed 
Symptoms
Palumbo 
2013
Le Fevre 
2013
Srivastava 
2014
Song 
2015
Lozano 
2015
Blanco-
Sánchez 2015
Sollis 
2016
Current 
Patient Total
De novo mutation + 9/9 + + + + 3/3 + 18/18
Low birthweight − 0/2 nd + nd nd nd + 2/5
FTT or small for age − 1/5 nd − nd nd nd + 2/8
Obesity − 2/5 nd − nd nd nd − 2/8
Prominent forehead + 4/7 nd + − + 2/3 +(1) 10/15
Macrocephaly − nd + nd + − 1/3 mild 4/8
Hypertelorism − nd nd nd − nd 2/3 + 3/6
Down slanted palpebral fissures + 3/7 nd − + + 1/3 + 8/15
Short nose with broad tip nd 4/7 nd + − + 2/3 + 9/14
Frontal hair upsweep nd 2/7 nd + − + nd − 4/11
Prominent digit pads nd 2/7 nd − nd nd nd − 2/9
Single palmar creases nd 1/7 nd − nd nd nd − 1/9
Clinodactyly nd 1/7 nd − nd nd nd + 2/9
Congenital anomalies(2) nd 3/8 nd + nd nd nd + 5/10
Global delay + 9/9 nd + + + 3/3 + 17/17
Regression nd 1/2 nd - nd nd nd − 1/4
Intellectual delay + 8/8 + + + + 3/3 + 17/17
Motor delay + 8/8 nd + + + 3/3 + 16/16
Speech and language delay + 9/9 nd + + + 3/3 + 17/17
Expressive language more severely 
affected than receptive language nd 7/7 nd + + + nd + 11/11
Articulation problems + 5/5 nd − + nd 3/3 + 11/12
Poor grammar nd 4/4 nd − + nd nd + 6/7
ASD/PDD-NOS + 3/4 nd − + nd 3/3 + 9/11
Autism + 2/4 nd − + nd 0/3 − 4/11
Behavioral problems + 4/5 nd − + nd 3/3 + 10/12
ADHD and/or sensory processing 
disorders + nd nd − + nd 2/3 + 5/7
Hypertonia nd 1/2(3) nd − − nd 0/3 + 2/8
Hypotonia + 1/2(3) + nd + nd 3/3 − 7/9
Reflexes nd 1/2 nd − nd nd nd + 2/4
Seizures nd 2/6 nd − nd nd nd − 2/8
Table 1. Clinical revision of FOXP1 patients. FTT: Failure to Thrive; ASD: Autistic Spectrum Disorders; PDD-
NOS: Pervasive Developmental Disorder Not Otherwise Specified; ADHD: Attention Deficit Hyperactivity 
Disorder; nd = no data. (1)The patient presented with trigonocephaly. (2)Including: contractures, spina bifida, 
Chiari 1 malformation, jejunal and ileal atresia, bilateral inguinal hernia25, bilateral cryptorchidism, horseshoe 
kidney (current patient) and hyperextension of the joins26. (3)One patient in Carr et al.21 presented with 
decreased axial tone and increased peripheral tone.
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at 4 limbs but was predominant at the legs, and there were neither distal contractures (present in Pariani et al.’s27 
patient) nor neuropathy.
To our knowledge, this is the first case of FOXP1 mutation associated with trigonocephaly, although other 
craniofacial anomalies such as prominent forehead are common in FOXP1 patients. Interestingly, FOXP1 neg-
atively regulates the expression of Runx213, a master transcription factor essential for bone development, whose 
haploinsufficiency produces cleidocranial dysplasia, which includes as main features patent sutures and fonta-
nelles. On the other hand, trigonocephaly is a relatively prevalent condition in the general population, and it 
might be due to an independent concomitant cause in this patient.
In conclusion, we describe a patient presenting with mental retardation, speech and language delay and minor 
craniofacial dysmorphic features, in whom the genetic cause of the disease, a de novo truncating mutation in 
FOXP1, could be identified, putting an end to 23 years of diagnostic uncertainty. To our knowledge, it is the first 
case of FOXP1 syndrome presenting with true trigonocephaly due to metopic synostosis, expanding the clinical 
spectrum of this syndrome.
Material and Methods
Biological samples. Genomic DNA from the patient and his parents was obtained from Istituto di Medicina 
Genomica, Università Cattolica Sacro Cuore, Rome. The signed informed consent was obtained from the patient’s 
mother, including explicit permission to share clinical and identifying information, including in on-line open-ac-
cess journals. All protocols were approved by the Ethics Committee of the Universitat de Barcelona and all meth-
ods were performed in accordance with the relevant guidelines and regulations.
Whole exome sequencing and molecular analyses. Whole exome sequencing of the proband was per-
formed in the National Center of Genomic Analysis (CNAG; Barcelona, Spain), using the Illumina HiSeq-2000 plat-
form. Exome capture was performed with Nimblegen SeqCap 64 Mb v3 (Roche; Mannheim; Germany). The samples 
where sequenced at a coverage of 50X. The data were analyzed as described elsewhere28. The results were then fil-
tered under de novo dominance and recessive hypotheses. Variants with a MAF above 0.001 (under the dominant) 
and above 0.01 (for recessive) in the common population (according to ExAC and 1000 genomes) were excluded. 
Variants in genes included in selected databases [The Development Disorder Genotype - Phenotype Database 
(DDG2P)]29,30 and covered by at least 10 reads were prioritized for validation (it should be noted that those who 
carried out the original DECIPHER analysis and collection of the data bear no responsibility for the further analysis 
or interpretation of it). In parallel, variant effects were classified as high, moderate or low according to SnpEff 31 and 
mutations with a high putative effect and at least 10 reads were also prioritized for validation by Sanger sequencing.
On average, the mean coverage for the patient was of 69 reads, and 93% of the target region was covered by at 
least 10 reads (C10). A total of 19 variants were selected for validation by Sanger sequencing. Primer sequences 
and PCR conditions are available on request. PCR reactions, purification and sequencing were performed as 
described previously14.
Minigene transcript analysis. In order to study the putative effect of the FOXP1 mutation on splic-
ing, a minigene was constructed, including the genomic region (ENST00000475937) that encompasses 
exons 15, 16 and 17 (1800pb). This region was PCR-amplified from the patient’s DNA using prim-
ers: FOXP1-MG-F (5′-CTCGAGTCCCAACTGGTGTCACCTAA-3′) and FOXP1-MG-R (5′-GGAT 
CCGAGCATTTCAACCACAATGG-3′). These primers include restriction sites for XhoI and BamHI, respectively 
(underlined). The wild-type and mutant PCR fragments were cloned into the pSPL3 vector (Addgene). Splicing was 
assessed 24 h after transfection in HeLa cells. RNA was extracted using the High Pure RNA isolation kit (Roche) and 
retro-transcribed using the High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). Primers SD6 
and SA2, specific for the pSPL3 vector, were used to amplify the spliced region. The PCR fragments were separated by 
agarose gel electrophoresis, purified and Sanger sequenced.
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